Phase 3 Readout
ANVS: Phase 3 Topline: A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial I
June 1, 2028. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 1, 2028
- Company
- Annovis Bio, Inc. (ANVS)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial I
- Company
- Annovis Bio, Inc. (ANVS)
- Indication
- Early Alzheimers Disease